Research programme: H1/NK1 antagonists - Sanofi-Aventis/Inflazyme
Alternative Names: H1/NK1 antagonists research programme - Aventis/Inflazyme; Histamine H1/neurokinin NK1 antagonists research programme - Aventis/Inflazyme; Research programme: histamine H1/neurokinin NK1 antagonists - Aventis/InflazymeLatest Information Update: 18 Mar 2009
At a glance
- Originator sanofi-aventis
- Class
- Mechanism of Action Histamine H1 receptor antagonists; Neurokinin 1 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Allergic conjunctivitis; Allergic rhinitis
Most Recent Events
- 12 Jun 2008 Discontinued - Preclinical for Allergic conjunctivitis in North America (Ophthalmic)
- 12 Jun 2008 Discontinued - Preclinical for Allergic rhinitis in North America (PO)
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis